Table 3.
Summary of studies investigating the use of SBRT for spine oligometastases; all BED calculations are based on an assumed α/β = 10 for the metastatic tumor
| Author, year | Study design | No. patientsNo. with CRC | No. spine metastasesNo. from CRC | SBRT dose and fractionation | BED, Gy | Local control outcomes, % | Survival outcomes, % | Grade 3 or greater toxicity, % |
|---|---|---|---|---|---|---|---|---|
| Chang et al. | phase I/II | 63 | 74 | 9 Gy × 3; | 48–51 | 84 (1 yr); | 70 (1 yr) | 4.8 |
| [65], 2004 | 1 | 1 | 6 Gy × 5 | 77 (2 yrs) | ||||
| Yamada et al. | retrospective | 93 | 103 | 18–24 Gy × 1 | 50–81 | 90 (15 mos; | 36 (45 mos) | 0 |
| [66], 2008 | 11 | NR | 95 for 24 Gy vs. | |||||
| 81 for 18–23 Gy) | ||||||||
| Amdur et al. | phase II | 21 | 25 | 15 Gy × 1 | 38 | 95 (8 mos) | 25 (1 yr) | 0 |
| [67], 2009 | 1 | 1 | ||||||
| Wang et al. | phase I/II | 149 | 166 | 9–10 Gy × 3 | 51–60 | 81 (1 yr); | 72 (1 yr); | 8 |
| [68], 2012 | 6 | NR | 73 (2 yrs) | 49 (2 yrs) | ||||
| Garg et al. | phase I/II | 61 | 63 | 16–24 Gy × 1 | 42–81 | 88 (18 mos) | 64 (18 mos) | 3.3 |
| [69],2012 | NR | NR |
SBRT = Stereotactic body radiation therapy; BED = biological effective dose; Gy = Gray; yr = year; yrs = years; mos = months; NR = not reported; CRC = colorectal cancer.